Trial: 201908038

A Phase III, Randomized Study of Nivolumab (OPDIVO) Plus AVD or Brentuximab Vedotin (ADCETRIS) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Phase

III

Principal Investigator

Bartlett, Nancy

Disease Site

Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov